Abstract
Methotrexate is being widely used in doses ranging from 500 to 2 000 mg administered as prolonged infusion over 12–36 h followed by leucovorin rescue to consolidate remission of acute lymphoblastic leukemia [1–4]. There is evidence that prolonged duration of exposure to methotrexate has a positive impact on the length of remission of ALL. Patients with a rapid systemic clearance of methotrexate have a higher risk of relapse [5–7].
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Similar content being viewed by others
References
Freeman AI, Brecher ML, Wang JJ, Sinks LF (1979) Intermediate dose methotrexate (IDM) in childhood acute lymphocytic leukemia (ALL). Hämatol Bluttransfus 23: 115–123
Moe PJ, Seip M, Finne PH (1981) Intermediate dose methotrexate (IDM) in childhood acute lymphocytic leukemia in Norway. Preliminary results of a national treatment program. Acta Paediatr Scand 70: 73–79
Janka GE, Mack R, Helmig M, Haas R, Bidlingmaier F (1984) Prolonged methotrexate infusions in children with acute leukemia in relapse and in remission and with medulloblastoma. Pharmacokinetics, toxicity and clinical results. Oncology 41: 225–232
Jürgens H (1983) Hochdosierte Methotrexatbehandlung. Indikation, Risiken, Steuerung. Urban and Schwarzenberg, Munich
Evans WE, Stewart CF, Chen CH et al. (1984) Methotrexate systemic clearance influences probability of relapse in children with standard risk acute lymphoblastic leukemia. Lancet ß: 359–362
Borsi JD, Moe PJ (1987) Systemic clearance of methotrexate in the prognosis of acute lymphoblastic leukemia in children. Cancer 60: 3020–3024
Borsi JD, Moe PJ (1990) Pharmacokinetics of methotrexate and folinic acid in children: an update. In: Borsi JP, Riccardi R (eds.) Role of clinical pharmacology in pediatric oncology. Workshop Proceedings, Rome
Janka GE, Winkler K, Jürgens H, Göbel U, Gutjahr P, Spaar HJ (1986) Akute lymphoblastische Leukämie im Kindesalter: Die COALL-Studien. Khn Pädiatr 198: 171–177
Janka-Schaub GE, Winkler K, Jürgens H, Göbel U, Gutjahr P, Spaar HJ (1986) Intermediate-dose methotrexate in the treatment of childhood acute lymphocytic leukemia: lack of benefit during maintenance therapy following intensive induction therapy. Eur J Pediatr 145: 14–17
Bleyer WA (1989) New vistas for leucovorin in cancer chemotherapy. Cancer 63: 995–1007
Borsi JD, Sagen E, Romslo I, Moe PJ (1990) Rescue after intermediate and high-dose methotrexate: background, rationale, and current practice. Pediatr Hematol Oncol 7: 347–363
Bleyer WA (1978) The clinical pharmacology of methotrexate. New applications of an old drug. Cancer 41: 36–51
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1992 Springer-Verlag Berlin Heidelberg
About this paper
Cite this paper
Jürgens, H., Janka, G., Ibrahim, M., Tonert, C., Winkler, K., Göbel, U. (1992). Prognostic Significance of Exposure to Intermediate-Dose Methotrexate in Children with Standard Risk ALL: The COALL 82/85 Experience. In: Hiddemann, W., Büchner, T., Wörmann, B., Plunkett, W., Keating, M., Andreeff, M. (eds) Acute Leukemias. Haematology and Blood Transfusion / Hämatologie und Bluttransfusion, vol 34. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-76591-9_54
Download citation
DOI: https://doi.org/10.1007/978-3-642-76591-9_54
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-540-53949-0
Online ISBN: 978-3-642-76591-9
eBook Packages: Springer Book Archive